Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Anish Suri Biography and Net Worth

Insider of Cue Biopharma

Anish Suri is an immunologist with extensive experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, including a key leadership position overseeing strategic Immunoscience initiatives. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University in St Louis, Missouri.

What is Anish Suri's net worth?: The estimated net worth of Anish Suri is at least $145,132.66 as of August 25th, 2023. Dr. Suri owns 135,638 shares of Cue Biopharma stock worth more than $145,133 as of December 18th. This net worth evaluation does not reflect any other assets that Dr. Suri may own. Additionally, Dr. Suri receives a salary of $447,340.00 as Insider at Cue Biopharma. Learn More about Anish Suri's net worth.
How old is Anish Suri?: Dr. Suri is currently 50 years old. There are 5 older executives and no younger executives at Cue Biopharma. The oldest executive at Cue Biopharma is Mr. Colin G. Sandercock J.D., MSE, Senior VP, General Counsel & Secretary, who is 67 years old. Learn More on Anish Suri's age.
What is Anish Suri's salary?: As the Insider of Cue Biopharma, Inc., Dr. Suri earns $447,340.00 per year. The highest earning executive at Cue Biopharma is Mr. Daniel R. Passeri J.D., M.Sc., CEO & Director, who commands a salary of $607,980.00 per year. Learn More on Anish Suri's salary.
How do I contact Anish Suri?: The corporate mailing address for Dr. Suri and other Cue Biopharma executives is 21 ERIE STREET, CAMBRIDGE MA, 02139. Cue Biopharma can also be reached via phone at (617) 949-2680 and via email at [email protected]. Learn More on Anish Suri's contact information.
Has Anish Suri been buying or selling shares of Cue Biopharma?: Anish Suri has not been actively trading shares of Cue Biopharma during the past quarter. Most recently, on Friday, August 25th, Anish Suri bought 4,000 shares of Cue Biopharma stock. The stock was acquired at an average cost of $2.76 per share, with a total value of $11,040.00. Following the completion of the transaction, the insider now directly owns 135,638 shares of the company's stock, valued at $374,360.88. Learn More on Anish Suri's trading history.
Who are Cue Biopharma's active insiders?: Cue Biopharma's insider roster includes Kerri-Ann Millar (CFO), Daniel Passeri (CEO), Kenneth Pienta (Insider), and Anish Suri (Insider). Learn More on Cue Biopharma's active insiders.
Are insiders buying or selling shares of Cue Biopharma?: In the last year, Cue Biopharma insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $30,900.00. The most recent insider tranaction occured on December, 16th when CEO Daniel R Passeri bought 30,000 shares worth more than $30,900.00. Insiders at Cue Biopharma own 12.3% of the company. Learn More about insider trades at Cue Biopharma.
Information on this page was last updated on 12/16/2024.

Anish Suri Insider Trading History at Cue Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2023	Buy	4,000	$2.76	$11,040.00	135,638
9/23/2021	Sell	20,000	$15.23	$304,600.00
8/5/2020	Sell	800	$20.01	$16,008.00	35,358
8/3/2020	Sell	5,800	$20.01	$116,058.00	36,558
12/21/2018	Buy	2,000	$4.37	$8,740.00

Anish Suri Buying and Selling Activity at Cue Biopharma

Cue Biopharma Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.07

$1.01

$1.22

50 Day Range

MA: $1.32

$0.94

$1.87

2 Week Range

Now: $1.07

$0.45

$3.20

Volume

451,012 shs

Average Volume

453,450 shs

Market Capitalization

$67.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Anish Suri Biography and Net Worth

What is Anish Suri's net worth?

How old is Anish Suri?

What is Anish Suri's salary?

How do I contact Anish Suri?

Has Anish Suri been buying or selling shares of Cue Biopharma?

Who are Cue Biopharma's active insiders?

Are insiders buying or selling shares of Cue Biopharma?